According to the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC (Ettinger et al., 2022), tyrosine kinase inhibitors (TKIs) are recommended as first-line therapy for patients with EGFR-mutant advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.